REGENERON PHARMACEUTICALS, INC. Gain (Loss) on Extinguishment of Debt
REGENERON PHARMACEUTICALS, INC. (REGN) reported Gain (Loss) on Extinguishment of Debt of -$30.10 million for the 12-month period ending 2017-12-31, per its 10-K filed 2019-02-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2019-02-07
- REGENERON PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for the quarter ending 2015-12-31 was $1.96M.
- REGENERON PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for the quarter ending 2015-09-30 was -$21.00K.
- REGENERON PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for the quarter ending 2015-06-30 was -$15.96M.
- REGENERON PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for the quarter ending 2015-03-31 was -$942.00K.
- REGENERON PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for fiscal 2017 was -$30.10M.
- REGENERON PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for fiscal 2015 was $18.86M.
- REGENERON PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for fiscal 2014 was -$33.47M.
- REGENERON PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for fiscal 2013 was $0.00.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 6 month as first filed | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 9 month as first filed | Gain (Loss) on Extinguishment of Debt 12 month | Gain (Loss) on Extinguishment of Debt 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2017-12-31 | -$30.10M 10-K · filed 2019-02-07 | ||||||
| 2015-12-31 | $1.96M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-08 | $1.94M derived: sum of 2 quarters · filed 2018-02-08 | -$14.02M derived: sum of 3 quarters · filed 2018-02-08 | $18.86M 10-K · filed 2018-02-08 | -$18.86M 10-K · filed 2016-02-11 | ||
| 2015-09-30 | -$21.00K 10-Q · filed 2015-11-04 | -$15.98M derived: sum of 2 quarters · filed 2015-11-04 | $16.90M 10-Q · filed 2016-11-04 | -$16.93M 10-Q · filed 2015-11-04 | -$39.61M derived: sum of 4 quarters · filed 2016-02-11 | ||
| 2015-06-30 | -$15.96M 10-Q · filed 2015-08-04 | $16.90M 10-Q · filed 2016-08-04 | -$16.91M 10-Q · filed 2015-08-04 | -$39.59M derived: sum of 3 quarters · filed 2016-02-11 | -$39.59M derived: sum of 4 quarters · filed 2016-02-11 | ||
| 2015-03-31 | -$942.00K 10-Q · filed 2015-05-07 | -$23.62M derived: sum of 2 quarters · filed 2016-02-11 | -$23.62M derived: sum of 3 quarters · filed 2016-02-11 | -$34.41M derived: sum of 4 quarters · filed 2016-02-11 | |||
| 2014-12-31 | -$22.68M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | -$22.68M derived: sum of 2 quarters · filed 2016-02-11 | -$33.47M derived: sum of 3 quarters · filed 2016-02-11 | -$33.47M 10-K · filed 2016-02-11 | |||
| 2014-09-30 | $0.00 10-Q · filed 2015-11-04 | -$10.79M derived: sum of 2 quarters · filed 2015-11-04 | -$10.79M 10-Q · filed 2015-11-04 | -$10.79M derived: sum of 4 quarters · filed 2016-02-11 | |||
| 2014-06-30 | -$10.79M 10-Q · filed 2015-08-04 | -$10.79M 10-Q · filed 2015-08-04 | -$10.79M derived: sum of 3 quarters · filed 2016-02-11 | -$10.79M derived: sum of 4 quarters · filed 2016-02-11 | |||
| 2014-03-31 | $0.00 10-Q · filed 2015-05-07 | $0.00 derived: sum of 2 quarters · filed 2016-02-11 | $0.00 derived: sum of 3 quarters · filed 2016-02-11 | $0.00 derived: sum of 4 quarters · filed 2016-02-11 | |||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | $0.00 derived: sum of 2 quarters · filed 2016-02-11 | $0.00 derived: sum of 3 quarters · filed 2016-02-11 | $0.00 10-K · filed 2016-02-11 | |||
| 2013-09-30 | $0.00 10-Q · filed 2014-11-04 | $0.00 derived: sum of 2 quarters · filed 2014-11-04 | $0.00 10-Q · filed 2014-11-04 | ||||
| 2013-06-30 | $0.00 10-Q · filed 2014-08-05 | $0.00 10-Q · filed 2014-08-05 | |||||
| 2012-12-31 | $0.00 10-K · filed 2015-02-12 | ||||||
| 2010-12-31 | $0.00 10-K · filed 2011-02-17 | ||||||
| 2009-12-31 | $0.00 10-K · filed 2011-02-17 | ||||||
| 2008-12-31 | -$938.00K 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |